INTERNATIONAL CONGRESS OF
CancerGenetics
Simultaneous omics and data analysis of breast cancer with a new generation chemotherapy drug
-
Majid Mesgartehrari,1,* Sheida Shadabi,2 Mohammad Mehdi ESlami,3 Saeid Mirlohi,4
- Introduction: In our research, we simulated new methods for diagnosing and treating breast cancer, such as the NGS method, as opposed to older methods like immunohistochemistry. Through this, we identified common mutations in breast cancer, including BRCA1, BRCA2, and BRIP1.
- Methods: In our research, we initially utilized the NCBI database to identify SNPs. Next, we compiled a list of breast cancer drugs available in Iran, along with their respective side effects. Finally, we used the MEGA GENE software to sort the SNPs based on citation and population, and then evaluated and analyzed the collected data.
- Results: Before prescribing drugs and therapy for the treatment of breast cancer, it is essential to conduct genetic tests to check for the presence of polymorphisms in common genes such as BRCA1, BRCA2, and BRIP1 in patients. If polymorphisms are present, drugs with fewer side effects should be prescribed for the patient.
- Conclusion: Based on the evaluations, we have determined the phenotypic manifestations resulting from the occurrence of these SNPs in the body. We have also identified the secondary phenotypes associated with breast cancer, as well as other diseases. Additionally, we have investigated the potential side effects of drugs used for treating breast cancer and the genetic predispositions that may influence the likelihood of experiencing these side effects in patients with suspected polymorphisms.
- Keywords: NGS- Genetic testing -Hereditary breast and ovarian cancer -BRCA1 - BRCA2
